Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1495233

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report

Provisionally accepted
Chiara Bernardi Chiara Bernardi 1,2*Yan Beauverd Yan Beauverd 1Thien-An Tran Thien-An Tran 1Marie Maulini Marie Maulini 1Maria Mappoura Maria Mappoura 1Sarah Morin Sarah Morin 1Federico Simonetta Federico Simonetta 1,2Anne Cairoli Anne Cairoli 3Holger W Auner Holger W Auner 3Kaveh Samii Kaveh Samii 1Yves Chalandon Yves Chalandon 1Carmen De Ramon Ortiz Carmen De Ramon Ortiz 1
  • 1 Division of Haematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland
  • 2 Translational Research Center for Oncohematology, Department of Medicine and Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Geneva, Switzerland
  • 3 Division of Haematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland

The final, formatted version of the article will be published soon.

    Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed/refractory (R/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.

    Keywords: bispecific Ab, Plasma cell leukemia (PCL), BCMA, GPRC5D, elranatamab, talquetamab

    Received: 12 Sep 2024; Accepted: 14 Nov 2024.

    Copyright: © 2024 Bernardi, Beauverd, Tran, Maulini, Mappoura, Morin, Simonetta, Cairoli, Auner, Samii, Chalandon and De Ramon Ortiz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chiara Bernardi, Division of Haematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.